Introduction 43
Moderate alcohol intake is associated with a lower risk of developing type 2 diabetes (1) and part of 44 this effect is thought to be mediated via its role in increasing adiponectin levels (2-6). Higher levels 45 of circulating adiponectin are alleged to be associated with a lower risk of type 2 diabetes (7) and 46 prediabetes (8), in addition to cardiovascular disease (9), various forms of cancer (10) and major 47 depression (11) . 48 However, the majority of studies linking alcohol intake to adiponectin rely on only one measure of 49 alcohol consumption at baseline and adiponectin level ascertained either cross-sectionally or at a 50 single follow-up occasion. It is important to consider the longitudinal development of both processes 51 to determine how, if at all, the two are related. However, studies with repeat measures of alcohol 52 consumption and adiponectin are scarce, so few studies have been able to examine the relationship 53 simultaneously. One study found that changes in drinking over a four year period, specifically the 54 uptake of modest drinking amongst initial non-drinkers and small increases in consumption amongst 55 light drinkers, were associated with higher adiponectin levels (12). However, this study was reliant on 56 a single measure of adiponectin at follow-up amongst only 697 men. Neither alcohol intake nor 57 circulating levels of adiponectin are static processes (13, 14) . That is, both change over time and it is 58 possible that accounting for the dynamic association between the two will shed additional light on the 59 role of alcohol intake in regulating adiponectin concentrations. The purpose of this study was 60 therefore to investigate how prospectively measured alcohol consumption is related to changes in 61 adiponectin levels over repeat measures.present data at phases 3 (1991-1993), 5 (1997-1999) and 7 (2002-2004 ) from a diabetes case-cohort 67 sample (16, 14) with measurements of adiponectin (N=3477 with at least one valid measure). We 68 excluded those with prevalent diabetes at baseline (N=17). Furthermore we limited our sample to 69 those who consumed alcohol at some point during follow-up to limit biases associated with lifelong 70 non-drinking and sick-quitting prior to baseline influencing our estimates (exclusion of N=110) 71 (17, 18) . Those with missing data on covariates were also excluded from the analytic sample (N=530), 72 resulting in a final sample size of 2,855 individuals (note missing data counts for categories above are 73 not mutually exclusive). Participants excluded from the analytic sample tended to be older, from 74 lower socioeconomic groups and of non-white ethnicity (there was no gender difference in 75 participation; data not presented). 76
The study was approved by the University College London Medical School Committee on the Ethics 77 of Human Research. Informed consent was obtained at baseline and renewed at each contact. 78
Whitehall II data, protocols, and other metadata are available to bona fide researchers for research 79 purposes. Please refer to the Whitehall II data sharing policy at http://www.ucl.ac.uk/whitehallII/data-80 sharing. 81
Measurements 82

Alcohol intake 83
Adiponectin 90
Adiponectin serum concentrations were measured using the Quantikine ELISA kit (R&D Systems, 91
Wiesbaden, Germany). The same standard operating procedures were followed for blood collection, 92
processing and storage during all study phases. Venous fasting (≥5 hour of fasting) blood samples 93 were drawn before a standard 2 hour oral-glucose tolerance test. Within an hour samples were 94 centrifuged on-site and serum immediately removed from the monovette tubes into microtubes stored 95 at −80°C. All assays were performed in the same laboratory (German Diabetes Center) and to 96 minimize imprecision samples from different study phases of the same participant were measured 97 using the same ELISA plate. The limit of detection was 3.9 ng/mL (all samples gave values above the 98 limit of detection). 99
Other covariates 100
We regressed the intercept and slope terms for both alcohol intake and adiponectin on the following 101 time-invariant covariates: age at baseline (centered on the sample mean), sex, ethnicity (white vs. non-102 white) and socioeconomic position defined using employment grade (high, intermediate or low 
values (25,26). 126
Both the intercepts (estimated values for log-transformed adiponectin and weekly alcohol intake at the 127 first study phase) and slopes (α terms) were fitted as random effects. Intercepts and slopes were 128 correlated within single processes (for example, the adiponectin intercept with the adiponectin slope) 129 and between processes (for example, the alcohol intercept with the adiponectin slope). See Figure 1  130 for a simplified graphical depiction of the model. As described above, intercepts and slopes were 131 estimated conditional on baseline covariates whilst smoking status was entered into the model as a 132 time-varying covariate. As adiponectin values (ng/mL) were heavily positively skewed we used 133 natural log-transformed values for analysis. 134
Models were estimated in Mplus version 7.3 (27) using Full Information Maximum Likelihood 135 (FIML) with Robust Standard Errors. Model fit was examined using the Tucker-Lewis index (TLI), 136 the comparative fit index (CFI), and the root mean squared error of approximation (RMSEA). Cut-off7 values approaching 0.95 were used to determine a good fit for TLI and CFI, while a threshold close to 138 0.06 was used for RMSEA (28). Statistical significance was inferred at a two-tailed P < 0.05.
139
Results
140
Descriptive statistics 141
Presented in Table 1 Table 2 alongside summaries of the proportion of current 146 smokers which also changed over time in the models estimated. The majority of the sample were non-147 smokers and the prevalence of current smoking declined over time. Mean alcohol intake at baseline 148 was almost 11 UK units per week, peaking at 14 units during follow-up before declining after this 149 (consistent with previous work (13)). Mean adiponectin levels declined throughout follow-up 150 (geometric means of 9.06, 9.05 and 9.03 at study phases 3, 5 and 7 respectively). 151
Regression estimates 152
Fit indices for all estimated models fell within the acceptable ranges reported above (data not shown). 153
Presented in Table 3 are regression coefficients and standard errors from a series of linear regression 154 models of the cross-sectional association between alcohol intake and log-transformed adiponectin 155 levels. In both age and sex as well as fully adjusted models higher alcohol intake was associated with 156 higher levels of circulating adiponectin (β ranging from 0.001 to 0.004 depending on phase and level 157 of adjustment; only the phase 3 fully adjusted did not meet the threshold for statistical significance 158 [P=0.12]). 159 Table 4 contains regression coefficients and standard errors for two bivariate dual change score 160 models, one with adjustment for age and sex only, and another with adjustment for ethnicity, adjusted model compared to β = -0.047), however, in both cases the association was not statistically 166 significant. 167
The effect of alcohol intake on upcoming change in adiponectin was non-significant in both models (γ 168 = -0.001 [SE 0.002] in age and sex adjusted, and γ = -0.002 [SE 0.002] in the fully adjusted model). 169
Conclusions 170
Summary of findings 171
Higher alcohol intake was associated with increased levels of adiponectin when measured cross-172 sectionally at all occasions, however, we found no evidence that alcohol consumption is associated 173 with changes in circulating levels of adiponectin over a 10 year period in a well-documented middle 174 age cohort of mostly white men and women. 175
Comparison to previous work 176
Our cross-sectional findings are broadly in agreement with existing studies on the topic of alcohol 177 intake and adiponectin -including interventional studies (6), however, our longitudinal findings are 178 not in line with other observational studies (12). The existing longitudinal studies have typically 179 examined the impact of a change in alcohol consumption between two measurement occasions on 180 adiponectin levels at a single point in time. In contrast, our primary focus was on predicting the 181 impact of alcohol consumption on changes in adiponectin levels over time. As such our findings 182 are not directly comparable. Whilst experimental studies have generally shown an association 183 between alcohol intake and higher adiponectin levels it is important to note that these effects are 184 limited to the short-term and there is substantial heterogeneity between them (6). It may therefore be that alcohol consumption is predictive of adiponectin levels acutely but not long term, and our 186 findings are broadly supportive of this. 187
Adiponectin was one of several plausible biomarkers recently put forward as having compelling 188 evidence in favour of it being a mediator in the relationship between moderate alcohol intake and 189 reduced risk of CHD and related conditions (11). Our findings cast doubt on this assertion and add to 190 the suspicion that a substantial proportion of the alleged protective effects of moderate alcohol intake 191 can be explained by misclassification bias, residual confounding and failing to longitudinal dynamics 192 between alcohol consumption and health over time (13, 22, 29 (31)).
Strengths and limitations 199
Our study is the largest investigation into the role of alcohol consumption on changes in adiponectin 200 that we are aware of, with a sample size of 2855 men and women compared to 697 men (12). Unlike 201 other studies we were also able to use repeat measures of both alcohol intake and adiponectin. This is 202 important as others have shown that accounting for variation in drinking over time is important when 203 predicting health outcomes (13,32).
204
Our study also has a number of limitations. For example, the Whitehall II study is not representative 205 of the general population, so there may be concerns regarding the generalisability of our findings to 206 the general population. However, it has been shown that aetiological associations observed inWe also concentrated on total adiponectin level but others have noted that multimetric forms of 209 adiponectin exist (e.g. high molecular weight oligomers, trimers and hexamers) and the association 210 between adiponectin levels and subsequent harm might be dependent on these different forms (21).
211
Unfortunately we did not have information on this. However, this is a shared limitation with previous 212 work looking at alcohol intake and adiponectin so should not impact comparisons made between our 213 work and the existing evidence base. 214
We also did not take into account beverage type, however, previous work has shown that beverage 215 preference is not associated with the development of type 2 diabetes (34) and others have noted that 216 often beverage specific effects are likely to be confounded by socioeconomic position (35-37).
217
Finally, we only considered total weekly alcohol intake. While this does not affect comparisons 218 between our work and existing studies that have used similar measures (12), it is nevertheless a 219 limitation, as others have shown that drinking pattern is an important determinant of harm. We were 220 unable to account for variation due to pattern of alcohol use per occasion (i.e. someone drinking 221 14 UK units per day may consume 2 UK units per day over the course of a week, or 222 alternatively reach their total intake by consuming 7 UK units on two occasions) -furthermore, it 223 has been demonstrated that even irregular bouts of heavy drinking amongst typically moderate 224 drinkers is associated with an increased risk of ill health (38).
Conclusion 226
We found that average weekly alcohol intake is associated with higher levels of adiponectin cross-227 sectionally but is not associated with changes in total circulating adiponectin levels over time. Future 228 work should examine the role of drinking pattern in the association between alcohol intake and 229 adiponectin, as well as different forms of adiponectin.
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